Medifocus Inc. (MDFZF) 0.0820 $MDFZF
Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Marketwired - Mon Dec 15, 7:30AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc.'s Technology Featured in a Mediaplanet Sponsored Insert in "USA Today" on Breast Cancer
Marketwire Canada - Fri Dec 05, 12:41PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announced that its sponsored Mediaplanet insert called "Breast Cancer Care Featuring Giuliana Rancic" has been distributed in today's issue to "USA Today" newspaper subscribers and newsstands throughout the US.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology
Marketwired - Tue Nov 25, 7:02AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that it has launched an advertising and marketing campaign in the U.S. to increase shareholder awareness geared specifically towards its Adaptive Phased Array (APA) Microwave Focusing Platform, for the treatment of breast cancer. The Company has received approvals from both the USA FDA and the Canadian Bureau of Medical Devices (BMD) to initiate the Pivotal Phase III breast cancer treatment study for the Company's APA 1000 Breast Cancer System, developed from the APA Microwave Focusing Platform.
MFS.VN: 0.095 (-0.005)
Medifocus Inc.'s Form 20-F Registration Statement Becomes Effective Immediately
Marketwired - Wed Nov 19, 4:07PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that its Registration Statement on Form 20-F that was filed with the U.S. Securities and Exchange Commission (the "SEC"
on September 17, 2014, as subsequently amended, has now become effective. As a result, Medifocus' common shares are now registered with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act" .
MFS.VN: 0.095 (-0.005)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 91.29 (+1.84), MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd and 24th
Marketwired - Thu Oct 23, 7:31AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be a sponsor at the upcoming VM Medical 20th Anniversary Breast Cancer Conference held on October 23rd and 24th, 2014 in Montreal, Canada. In addition, Medifocus will present a Poster on its "Wide-Field Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-based Chemotherapy to Increase Local Response for Improved Breast Conservation Potential. The Pivotal Phase III breast cancer treatment study has been approved by both the USA Food and Drug Administration and also the Canadian Bureau of Medical Devices (BMD). Dr. John R. Keyserlingk, MD, is the Principal Investigator in Canada at the VM Med (Ville Marie Medical Center) in Montreal, Canada. The USA Principal Investigational site has already been initiated at the University of Oklahoma Breast Institute under the supervision of our USA Principal Investigator, Dr. William C. Dooley, MD. The goal of the 238-patient Medifocus-sponsored randomized Phase III study is to demonstrate that preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) thus reducing the need of a mastectomy. Further details of the Medifocus, Inc. Pivotal Phase III study are published on the www.clinicaltrials.gov web site. The Medifocus, Inc. APA-1000 system used in this clinical trial is based on focused microwave thermotherapy technology exclusively licensed from the Massachusetts Institute of Technology (MIT).
MFS.VN: 0.095 (-0.005)
Medifocus Inc. Announces Closing of Private Placement
Marketwire Canada - Mon Sep 15, 7:44AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of a private placement of 10,281,250 Units at a price of US$0.16 per Unit for gross proceeds of US$1,645,000. Each Unit is comprised of one common share (a Common Share) and one Series D Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to purchase one additional Common Share at a price of US$0.25 for a period of 36 months following the completion of the offering. If, at any time after the date that is 12 months following the Closing Date, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or its equivalent in U.S. dollars) for at least 20 consecutive trading days, the Company may, within 30 days of such occurrence, provide an expiry acceleration notice to the holders of Series D Warrants and, if it does so, the Series D Warrants will, unless exercised, expire on the 30th day after the acceleration notice is given.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Announces Financial Results for the Fiscal First Quarter Ending June 30, 2014
Marketwire - Wed Sep 10, 7:45AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), reported its financial results for the fiscal first quarter ending June 30, 2014 which shows a 32% increase in revenues over the prior year's first quarter.
MFS.VN: 0.095 (-0.005)
Medifocus Announces Retraction of Prior Press Release
Marketwire - Mon Sep 08, 6:14PM CDT
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) (Medifocus) issued a press release earlier today regarding the initiation of research coverage by SeeThruEquity that inadvertently included a target price from the research report. Medifocus hereby retracts this press release.
MFS.VN: 0.095 (-0.005)
SeeThruEquity Initiates Research Coverage on Medifocus Inc. With Target Price of $0.52
Marketwire - Mon Sep 08, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, has initiated coverage on Medifocus, Inc. with a target price of $0.52. The report is available at: http://www.seethruequity.com/.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Marketwired - Mon Dec 15, 7:30AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc.'s Technology Featured in a Mediaplanet Sponsored Insert in "USA Today" on Breast Cancer
Marketwire Canada - Fri Dec 05, 12:41PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announced that its sponsored Mediaplanet insert called "Breast Cancer Care Featuring Giuliana Rancic" has been distributed in today's issue to "USA Today" newspaper subscribers and newsstands throughout the US.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology
Marketwired - Tue Nov 25, 7:02AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that it has launched an advertising and marketing campaign in the U.S. to increase shareholder awareness geared specifically towards its Adaptive Phased Array (APA) Microwave Focusing Platform, for the treatment of breast cancer. The Company has received approvals from both the USA FDA and the Canadian Bureau of Medical Devices (BMD) to initiate the Pivotal Phase III breast cancer treatment study for the Company's APA 1000 Breast Cancer System, developed from the APA Microwave Focusing Platform.
MFS.VN: 0.095 (-0.005)
Medifocus Inc.'s Form 20-F Registration Statement Becomes Effective Immediately
Marketwired - Wed Nov 19, 4:07PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that its Registration Statement on Form 20-F that was filed with the U.S. Securities and Exchange Commission (the "SEC"
on September 17, 2014, as subsequently amended, has now become effective. As a result, Medifocus' common shares are now registered with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act" . MFS.VN: 0.095 (-0.005)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 91.29 (+1.84), MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd and 24th
Marketwired - Thu Oct 23, 7:31AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be a sponsor at the upcoming VM Medical 20th Anniversary Breast Cancer Conference held on October 23rd and 24th, 2014 in Montreal, Canada. In addition, Medifocus will present a Poster on its "Wide-Field Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-based Chemotherapy to Increase Local Response for Improved Breast Conservation Potential. The Pivotal Phase III breast cancer treatment study has been approved by both the USA Food and Drug Administration and also the Canadian Bureau of Medical Devices (BMD). Dr. John R. Keyserlingk, MD, is the Principal Investigator in Canada at the VM Med (Ville Marie Medical Center) in Montreal, Canada. The USA Principal Investigational site has already been initiated at the University of Oklahoma Breast Institute under the supervision of our USA Principal Investigator, Dr. William C. Dooley, MD. The goal of the 238-patient Medifocus-sponsored randomized Phase III study is to demonstrate that preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) thus reducing the need of a mastectomy. Further details of the Medifocus, Inc. Pivotal Phase III study are published on the www.clinicaltrials.gov web site. The Medifocus, Inc. APA-1000 system used in this clinical trial is based on focused microwave thermotherapy technology exclusively licensed from the Massachusetts Institute of Technology (MIT).
MFS.VN: 0.095 (-0.005)
Medifocus Inc. Announces Closing of Private Placement
Marketwire Canada - Mon Sep 15, 7:44AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of a private placement of 10,281,250 Units at a price of US$0.16 per Unit for gross proceeds of US$1,645,000. Each Unit is comprised of one common share (a Common Share) and one Series D Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to purchase one additional Common Share at a price of US$0.25 for a period of 36 months following the completion of the offering. If, at any time after the date that is 12 months following the Closing Date, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or its equivalent in U.S. dollars) for at least 20 consecutive trading days, the Company may, within 30 days of such occurrence, provide an expiry acceleration notice to the holders of Series D Warrants and, if it does so, the Series D Warrants will, unless exercised, expire on the 30th day after the acceleration notice is given.
MFS.VN: 0.095 (-0.005)
Medifocus, Inc. Announces Financial Results for the Fiscal First Quarter Ending June 30, 2014
Marketwire - Wed Sep 10, 7:45AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), reported its financial results for the fiscal first quarter ending June 30, 2014 which shows a 32% increase in revenues over the prior year's first quarter.
MFS.VN: 0.095 (-0.005)
Medifocus Announces Retraction of Prior Press Release
Marketwire - Mon Sep 08, 6:14PM CDT
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) (Medifocus) issued a press release earlier today regarding the initiation of research coverage by SeeThruEquity that inadvertently included a target price from the research report. Medifocus hereby retracts this press release.
MFS.VN: 0.095 (-0.005)
SeeThruEquity Initiates Research Coverage on Medifocus Inc. With Target Price of $0.52
Marketwire - Mon Sep 08, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, has initiated coverage on Medifocus, Inc. with a target price of $0.52. The report is available at: http://www.seethruequity.com/.
MFS.VN: 0.095 (-0.005)
